Translate Fellowship Program Leadership
Jennifer C. Kesselheim, MD, M.Ed, MBE
Pediatric Hematology/Oncology Fellowship Program Director, Division of Hematology/Oncology; Associate Professor of Pediatrics, Harvard Medical School
Dr. Kesselheim attended college at the University of Wisconsin and completed her MD at the University of Pennsylvania, where she also earned a master’s in bioethics. Following medical school, she completed residency training in the Boston Combined Residency Program in pediatrics. As a resident, Dr. Kesselheim developed bioethics curricula, and she began to conduct national studies to assess the outcomes of ethics education in pediatric training. Her focus at the interface of ethics, professionalism, and medical education led her to pursue a master’s degree in education from Harvard University, which she completed while a fellow in pediatric hematology/oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute. As an educator, Dr. Kesselheim directs the Pediatric Hematology/Oncology Fellowship Program at Dana-Farber/Boston Children’s, where she also cares for patients with hematologic malignancies. From 2013-2021, she served as the inaugural Director of the Master of Medical Science (MMSc) in Medical Education based at Harvard Medical School, a two-year graduate program blending coursework in medical education with mentored research. In 2021, she transitioned to Director of Graduate Medical Education and DIO at Boston Children's Hospital. Dr. Kesselheim’s research investigates the methods and outcomes of physician education in the areas of humanism, ethics, and professionalism. Her projects also pertain to integrating interprofessional education into medical school, assessment in pediatric residency and fellowship, and fostering diversity during recruitment of residents and fellows. Dr. Kesselheim lives in Boston with her husband, Aaron; son, Max (age 14); daughter, Sydney (age 10); and son, Leo (age 7).
Angela M. Feraco, MD, MMSc
Associate Program Director, Pediatric Hematology/Oncology Fellowship Program; Assistant Professor of Pediatrics, Harvard Medical School
Dr. Feraco is a pediatric oncologist whose scholarship focuses on communication and interprofessional collaboration in the care of children with cancer. Dr. Feraco received her MD from the University of California, San Francisco. She served as a pediatric resident and chief resident in the Boston Combined Residency Program and completed her fellowship training in pediatric hematology/oncology at Dana-Farber/Boston Children’s. Dr. Feraco completed a master’s degree in medical education at Harvard Medical School and is active in graduate medical education leadership locally and nationally. She directs the core educational curriculum for first-year fellows and runs the pediatric oncology resident rotation. In her role as Associate Program Director, Dr. Feraco focuses on the interface between the training program and clinical operations.
Katie A. Greenzang, MD, EdM
Associate Program Director, Pediatric Hematology/Oncology Fellowship Program; Assistant Professor of Pediatrics, Harvard Medical School
Dr. Greenzang is a pediatric oncologist and investigator whose research focuses on optimizing patient-provider communication and shared treatment decision-making, with a specific focus on late effects of cancer and pediatric cancer survivorship. Dr. Greenzang graduated from Harvard University and attended medical school at Columbia University Vagelos College of Physicians and Surgeons. She completed her pediatrics residency and chief residency at the University of Washington’s Seattle Children’s Hospital, and her fellowship training in pediatric hematology/oncology at Dana-Farber/Boston Children’s. Medical education is also a focus of Dr. Greenzang’s career; she received a master's in education from the Harvard Graduate School of Education as a Zuckerman Fellow, and she is a former Harvard Medical School Academy Medical Education Fellow. Dr. Greenzang teaches and leads several courses at Harvard Medical School, and she conducts research on the development of communication skills and professionalism. As an Associate Program Director, Dr. Greenzang gives dedicated attention to fellow well-being, recruitment, and the overall learning environment.
Kee Kiat (Aaron) Yeo, MD
Associate Program Director, Pediatric Hematology/Oncology Fellowship Program; Assistant Professor of Pediatrics, Harvard Medical School
Dr. Yeo is a pediatric neuro-oncologist whose research focus is in the development of novel therapeutics and the cancer care of adolescent and young adults with central nervous system tumor. Dr. Yeo was born and raised in Malaysia, before moving to the United States for medical school, where he received his MD from Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania. Dr. Yeo completed his pediatric residency at Children’s National Hospital, before undergoing fellowship training in pediatric hematology/oncology and pediatric neuro-oncology at Children’s Hospital Los Angeles. Dr. Yeo also serves as the program director for the pediatric neuro-oncology fellowship at Dana-Farber / Boston Children’s Cancer and Blood Disorders Center.
Suneet Agarwal, MD, PHD
Director of Fellowship Research, Pediatric Hematology/Oncology Fellowship Program
Associate Professor of Pediatrics at Harvard Medical School
Dr. Suneet Agarwal is a physician-scientist in the bone marrow failure and hematopoietic stem transplant programs in the Dana-Farber/Boston Childen’s Cancer and Blood Disorders Center. Dr. Agarwal completed his Sc.B in Biochemistry at Brown University followed by M.D. / Ph.D. training at Harvard Medical School. He undertook pediatrics residency training in the Boston Combined Residency Program, followed by a fellowship in hematology/oncology at Boston Children's Hospital /Dana-Farber Cancer Institute, where he served as Chief Fellow. He conducted postdoctoral research with Dr. George Daley in stem cell biology at Boston Children's Hospital. Dr. Agarwal's current research efforts at Boston Children's Hospital are centered around rare genetic blood diseases. His research lab investigates basic mechanisms of telomere and mitochondrial biology and associated human disorders, with active efforts to develop first-in-class therapeutics. He is also principal investigator of an international multi-center stem cell transplant trial for bone marrow failure disorders associated with short telomeres. As an Associate Program Director, Dr. Agarwal is focused on advising fellows as they define their research direction and mentorship plans and fostering their development into successful independent investigators.
David A. Williams, MD
Associate Chairman, Department of Pediatric Oncology, Dana-Farber Cancer Institute; Chief, Hematology/Oncology, Boston Children's Hospital; Leland Fikes Professor of Pediatrics, Harvard Medical School
Dr. Williams formerly served as the Executive Vice President and Chief Scientific Officer at Boston Children's Hospital and Chief of Hematology/Oncology at Boston Children’s Hospital. He was a Howard Hughes Medical Institute Investigator for 16 years and his laboratory has been continuously funded by the NIH since 1986. He has trained over 45 fellows and post-doctoral fellows and numerous residents and medical students in his laboratory, the majority of which are still in academic medicine. He is a member of the National Academy of Medicine and has published over 300 peer-reviewed manuscripts and textbook chapters. He formerly served on the NIH Recombinant DNA Advisory Committee and Gene Therapy Safety Assessment Board. He is actively involved in gene therapy trials for hematological, immunodeficiency, and neurological genetic diseases and has been the investigator, co-investigator or sponsor (IND holder) of multiple previous gene therapy trials and is sponsor or investigator of four current trials. He served as the Editor-In-Chief of Molecular Therapy from 2004-2009 and is co-founder of the Transatlantic Gene Therapy Consortium and the North American Pediatric Aplastic Anemia Consortium (NAPAAC). His basic research has focused on hematopoietic stem cell biology, including genetic diseases of the blood and specifically molecular and biochemical analysis of the interaction between hematopoietic stem cells and the bone marrow supporting environment. His laboratory has significant experience in stem cell biology, hematopoiesis, and gene correction and transfer techniques. His research has described the molecular basis for two rare immunodeficiency diseases due to mutations of RAC2 and RHOH, members of the RHO GTPase family of signaling molecules. He has multiple patents of which two have been developed into FDA-approved drugs (Neumega™ and Retronectin™) and is co-founder of two biotech companies, Orchard Therapeutics and Alerion Biosciences. Dr. Williams is a past President of the International Society of Experimental Hematology and the American Society of Hematology. He continues active clinical service in non-malignant hematology in-patient, and bone marrow failure ambulatory settings.
Kimberly Stegmaier, MD
Chair of Department of Pediatric Oncology, Dana-Farber Cancer Institute
Ted Williams Chair, Dana-Farber Cancer Institute
Associate Chief, Division of Hematology/Oncology, Boston Children's Hospital
Professor of Pediatrics, Harvard Medical School
Institute Member, Broad Institute
Kimberly Stegmaier, MD, is Chair of the Department of Pediatric Oncology, Dana-Farber Cancer Institute; Associate Chief, Division of Hematology/Oncology at Boston Children's Hospital; Professor of Pediatrics at Harvard Medical School; and currently the Ted Williams Chair at Dana-Farber Cancer Institute. She has been a faculty member at Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School since 2002 and an independent investigator since 2006. Dr. Stegmaier is dedicated to the goal of precision pediatric oncology medicine, pioneering the development and application of innovative genomic approaches to identify new therapies for childhood cancer. She has focused her efforts on acute leukemias and pediatric solid tumors of childhood — particularly those driven by fusion oncoproteins. Her lab has discovered novel technologies, concepts, and targets with translational impact.
Dr. Stegmaier received her undergraduate degree from Duke University, and medical degree from Harvard Medical School, and completed training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute.